Healome Therapeutics Raises £2 Million in Seed Funding
Healome Therapeutics, a Birmingham-based company specializing in developing novel treatments for restoring function in diseased and damaged tissues, has successfully raised £2 million in a seed funding round. This funding round, completed on July 7, 2026, was led by Empirical Ventures, with participation from Cure EB, DEBRA Research, Oshen Bio, and SFC Capital.
Focus on Ocular Surface Diseases
Healome Therapeutics is currently concentrating its efforts on ocular surface diseases. The company aims to innovate in the field of vision health by creating treatments that can effectively restore the function of damaged tissues in the eye. This focus aligns with the growing need for advanced solutions in treating various eye conditions that affect millions worldwide.
Leadership and Vision
The company is helmed by CEO Richard Williams, who has been instrumental in steering the company's direction towards impactful medical innovations. Williams has emphasized the importance of this funding round, stating, "This investment is a significant milestone for us as we continue our work on developing treatments that have the potential to change lives."
Strategic Use of Funds
The newly acquired capital is expected to be used primarily to accelerate the development of their ocular treatment pipeline. This includes advancing clinical trials and expanding research capabilities to ensure that their solutions can reach the market more swiftly.
Investor Confidence
The participation of a diverse group of investors, including Empirical Ventures, Cure EB, DEBRA Research, Oshen Bio, and SFC Capital, underscores the confidence the investment community has in Healome Therapeutics' approach and potential impact in the field of regenerative medicine.
Looking Ahead
With this financial backing, Healome Therapeutics is well-positioned to make significant strides in its mission to provide innovative treatment options for ocular diseases. The company's progress will be closely watched by both the medical community and investors as they work towards launching their therapies.